Feb 20, 2018   SOURCE: PR NewsWire

NeuroVive Pharmaceutical AB Year End Report January - December 2017

STOCKHOLM, Feb. 20, 2018 /PRNewswire/ --

Business operations

Significant events October-December 2017

    --  NeuroVive received a positive opinion from the EMA's Committee for
        Orphan Medicinal Products (COMP) regarding orphan drug designation for
        KL1333.
    --  Greg Batcheller, the Chairman of NeuroVive's Board for the past 17
        years, resigned on November 6. The Board elected David Laskow-Pooley as
        the new Chairman.
    --  On November 3, 2017, NeuroVive issued shares totaling SEK 5.3 million
        before transaction costs through a private offering to Floyd Associates
        Europe Limited.
    --  NeuroVive and Lund University were granted funding by the Swedish
        Foundation for Strategic Research (SSF) for collaboration around liver
        cancer research.
    --  NeuroVive signed a collaboration agreement with the University of
        Florida for TBI biomarker development.
    --  NeuroVive presented results from preclinical TBI trials related to the
        NeuroSTAT project at the 2017 Nordic Neurotrauma Conference.
    --  NeuroVive presented its innovative metabolic regulators for the
        non-alcoholic steatohepatitis (NASH) liver disease at the Annual Meeting
        of the American Association for the Study of Liver Diseases (AASLD) on
        October 20-24, 2017 in Washington DC, USA.
    --  NeuroVive's partner, the Children's Hospital of Philadelphia (CHOP), was
        granted research funding by the US National Institutions of Health (NIH)
        to study NeuroVive's NVP015 compounds as countermeasures against
        chemical threats.
    --  NeuroVive selected a candidate compound in the NVP015 project for
        mitochondrial disorders for continued preclinical development.
    --  NeuroVive reported progress in the Korean Phase I trial of KL1333.
    --  KL1333 was granted orphan drug designation by the European Commission

Important events after the end of the period

    --  NeuroVive reported a breakthrough for the NVP025 project for
        mitochondrial myopathies.
    --  The Board of Directors of NeuroVive has resolved, subject to approval by
        the Extraordinary General Meeting, to issue shares and warrants with
        preferential rights for existing shareholders. Upon full subscription to
        the rights issue, NeuroVive will receive approximately MSEK 78.5 before
        issuance costs. In full exercise of the warrants issued in the Rights
        issue, NeuroVive will receive an additional MSEK 37.3 before issuance
        costs.

Financial information

Fourth quarter (October-December 2017)

    --  Net revenues were SEK 0 (14,000) and other operating income was SEK
        9,000 (14,000)
    --  Loss before tax was SEK 14,779,000 (loss: 14,580,000)
    --  Loss per share* was SEK 0.29 (loss: 0.34)
    --  Diluted loss per share** was SEK 0.29 (loss: 0.34)

Full-year (January-December 2017)

    --  Net revenues were SEK 27,000 (14,000) and other operating income was SEK
        558,000 (104,000)
    --  Loss before tax was SEK 71,603,000 (loss: 71,845,000)
    --  Loss per share* was SEK 1.33 (loss: 1.67)
    --  Diluted loss per share** was SEK 1.33 (loss: 1.67)

* Profit/loss for the period divided by average number of shares before dilution at the end of the period.

** Profit/loss for the period divided by average number of shares after dilution at the end of the period.

The complete Year End report is available for download below and through the NeuroVive web site www.neurovive.com.

For more information concerning this report, please contact CEO Erik Kinnman. Telephone: +46 (0)46-275-62-20.

The information was submitted for publication, through the agency of the contact person set out above, at 08:30 a.m. CET on 20 February 2018.

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
www.neurovive.com

About NeuroVive

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. The company's strategy is to advance drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/neurovive-pharmaceutical/r/neurovive-pharmaceutical-ab-year-end-report-january---december-2017,c2455776

The following files are available for download:


    http://mb.cision.com/Main/6574/2455776/794559.pdf PDF

View original content:http://www.prnewswire.com/news-releases/neurovive-pharmaceutical-ab-year-end-report-january---december-2017-300600974.html

SOURCE NeuroVive Pharmaceutical